AVADEL PHARMACEUTICALS PLC Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020
Cash flows from operating activities:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization
Impairment of intangible asset
Remeasurement of acquisition-related contingent consideration
Remeasurement of financing-related contingent consideration
Amortization of debt discount and debt issuance costs
Changes in deferred taxes
Share-based compensation expense
Gain on sale of Hospital Products
Loss on deconsolidation of subsidiary
Other adjustments
Net changes in assets and liabilities
Accounts receivable
Inventories
Prepaid expenses and other current assets
Research and development tax credit receivable
Accounts payable & other current liabilities
Deferred revenue
Accrued expenses
Earn-out payments for contingent consideration in excess of acquisition-date fair value
Royalty payments for contingent consideration payable in excess of original fair value
Other assets and liabilities

Net cash used in operating activities
Cash flows from investing activities:
Purchases of property and equipment
Proceeds from disposal of property and equipment
Proceeds from the disposition of the Hospital Products
Purchase of intangible assets
Proceeds from sales of marketable securities
Purchases of marketable securities
Net cash provided by (used in) investing activities

Cash flows from financing activities:
Proceeds from the February 2020 private placement
Proceeds from the May 2020 public offering
Proceeds from issuance of shares, net of issue costs
Public offering
At-the-market offering program
Total proceeds from issuance of shares, net of issue costs
Proceeds from stock option exercises and employee share purchase plan
Share repurchases
Other financing activities, net
Payments for Notes
February 2023 Notes
October 2023 Notes
Payments for debt issuance costs
Payments for extinguishment of February 2023 Notes
Proceeds from royalty purchase agreement
Exercise of warrants
Net cash provided by financing activities

Effect of foreign currency exchange rate changes on cash and cash equivalents
Net change in cash and cash equivalents
Cash and cash equivalents at January 1
Cash and cash equivalents at December 31
Supplemental disclosures of cash flow information:
Interest paid
Income taxes refunded, net

Comments